Vitamin D-related therapies in prostate cancer

Cancer and Metastasis Reviews

Volumn 21, Issue 2, 2002, Pages 147-158

  Johnson, Candace S ^a   Hershberger, Pamela A ^b   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Calcitriol; Preclinical studies; VDR; Vitamin D; Vitamin D analogues

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; ANDROGEN; CALCITRIOL; CARBOPLATIN; CASPASE; DEXAMETHASONE; GLUCOCORTICOID; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SEOCALCITOL; VITAMIN D; VITAMIN D RECEPTOR; DRUG DERIVATIVE;

ADVANCED CANCER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; KIDNEY FAILURE; MALE; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; UROLITHIASIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; PROSTATE TUMOR; REVIEW; VITAMIN D RESPONSIVE ELEMENT;

ANIMALS; CALCITRIOL; HUMANS; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; VITAMIN D; VITAMIN D RESPONSE ELEMENT;

EID: 0036432903     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020836226594     Document Type: Article

References (113)

1. Bikle DD, Pillai S: Vitamin D, calcium, and epidermal differentiation. Endocrine Rev 14: 3-19, 1993
2. Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. New Engl J Med 320: 980-991, 1989
3. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1998
4. Darwish HM, DeLuca HF: Recent advances in the molecular biology of vitamin D action. In: Progress in Nucleic Acid Research and Molecular Biology, Vol 53, Academic Press Inc, 1996, pp 321-344
5. Christakos S, Raval-Pandya M, Wernyj RP, Yang W: Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316: 361-371, 1996
6. Darwish H, DeLuca HF: Vitamin D-regulated gene expression. Critical Reviews in Eukaryotic Gene Expression 3(2): 89-116, 1993
7. Studzinski GP, McLane JA, Uskokovic MR: Signaling pathways for vitamin D-induced differentiation: Implications for therapy of proliferative and neoplastic diseases. Critical Reviews in Eukaryotic Gene Expression 3(4): 279-312, 1993
8. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P: Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66: 121-127, 1998
9. Stevens A, Lowe JS: Male reproductive system. In: Stevens A, Lowe JS (eds) Histology, Gower Medical Publishing, London, 1992, pp 304-321
10. Weigel NL: Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319: 657-667, 1996
11. Kuiper GGJM, Brinkmann AO: Steroid hormone receptor phosphorylation: Is there a physiological role? Mol Cell Endocrin 100: 103-107, 1994
12. 2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol 41: 231-240, 1992
13. Slater SJ, Kelly MB, Taddeo, FJ, Larkin JD, Yeager MD, McLane JA, Ho C, Stubbs CD: Direct activation of protein kinase C by 1α,25-dihydroxyvitamin D3. J Biol Chem 270: 6639-6643, 1995
14. 2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem 269: 8675-8679, 1993
15. 3 in CaCo-2 cells. Endocrinology 135: 277-283, 1994
16. De Boland AR, Norman AW: Evidence for involvement of protein kinase C and cyclic adenosine 3′,5′ monophosphate-dependent protein kinase in the 1,25-dihydroxyvitamin D3-mediated rapid stimulation of intestinal calcium transport (transcaltachia). Endocrinology 127: 39, 1990
17. 3 in normal human keratinocytes. J Invest Derm 106: 1212-1217, 1996
18. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56: 4108-4110, 1996
19. Ingles SA, Ross RK, Yu MC, Irvine RA, Lapera G, Halle RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170, 1997
20. Kibel AS, Isaacs SD, Isaacs WB, Bova GS: Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 160: 1405-1409, 1998
21. Morrison AN, Qi CJ, Tokita A: Prediction of bone density from vitamin D recptor alleles. Nature 67: 284-297, 1994
22. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7: 385-390, 1998
23. Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861-2869, 1992
24. Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10: 1307-1312, 1990
25. Wu LY, Semenya KA, Hardy RE, Hargreaves MK, Robinson SB, Pederson L, Sung JF, Haynes MA: Cancer rate differentials between blacks and whites in three metropolitan areas: A 10-year comparison. J Natl Med Assoc 90: 410-416, 1998
26. Haenszel W, Jurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43-68, 1968
27. Holick MF: The photobiology of vitamin D3 in man. In: Kumar R (ed) Vitamin D: Basic and Clinical Aspects, Martinus Nijhoff, Boston, 1984, pp 197-216
28. kip1 and E-cadherin. J Mol Endocrinol 19: 15-27, 1997
29. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14: 1077-1081, 1994
30. Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP: 19-nor-26,27-bishomo-vitamin D3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58: 3370-3374, 1998
31. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ: Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3: 1331-1338, 1997
32. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR: 1,24-Dihydroxy-16-ene-23-yne-vitamin D and prostate cancer cell proliferation in vivo. Urology 46: 365-369, 1995
33. Campbell MJ, Reddy GS, Koeffler HP: Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66: 413-425, 1997
34. Hansen CM, Maenpaa PH: EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 54: 1173-1179, 1997
35. Kissmeyer AM, Binderup E, Binderup L, Hansen M, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G: Metabolism of the vitamin D analog EB1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 53: 1087-1097, 1997
36. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC: A phase I study of vitamin D analogue EB 1089 in patients with advanced breast and colorectoral cancer. Br J Cancer 78: 6-13, 1998
37. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR: 1,25-Dihydroxyvitamin D3 induced differentiation in a human promyelocytic leukemia cell line HL-60: Receptor mediated maturation to macrophage-like cells. J Cell Biol 98: 391-398, 1984
38. Zhou JY, Norman AW, Chen DL: 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87: 3929-3932, 1990
39. Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44: 693-702, 1993
40. Frappart L, Falette N, Lefebvre MF, Bremond A, Vauzelle JL, Saez S: In vitro study of effects of 1,25-dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT.20. Differentiation 40: 63-69, 1989
41. Shabahang M, Buras RR, Davoodi F, Schmaker LM, Nauta RJ, Evans SR: 1,25-Dihydroxyvitamin D3 receptors as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53(16): 3712-3718, 1993
42. 3 on primary cultures of human prostatic cells. Cancer Res 54: 805-810, 1994
43. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P: The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1,25-dihydroxyvitamin D3. Cancer Res 52: 515-520, 1992
44. Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocr 132: 1952-1960, 1993
45. de Vos S, Holden S, Heber D, Elstner E, Binderup L, Uskokovic M, Rude B, Chen D, Le J, Cho SK, Koeffler HP: Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 31: 77-83, 1997
46. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP: 1α,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6: 727-732, 1997
47. Godyn JJ, Xu H, Zhang F, Kolla SS, Studzinski GP: A dual block to cell cycle progression in HL-60 cells exposed to analogues of vitamin D3. Cell Proliferation 27: 37-46, 1994
48. Rigby WF, Noelle RJ, Krause K, Fanger MW: The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: A cell cycle analysis. J Immunol 135: 2279-2286, 1985
49. Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56: 264-267, 1996
50. Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP: Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes & Devel 10: 142-153, 1996
51. Biggs JR, Kraft AS: Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73: 509-514, 1995
52. 1 cyclin-dependent kinases. Genes & Devel 9: 1149-1163, 1995
53. WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11(9): 1899-1905, 1995
54. Henkart PA: ICE family proteases: Mediators of all apoptotic cell death? Immunity 4: 195-201, 1996
55. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond) 348: 334-336, 1990
56. Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 4: 413-420, 1992
57. Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
58. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58: 367-376, 1996
59. Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, Shintaku IP, Krajewski S, Reed JC, Binderup L, Koeffler HP: Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56: 3570-3576, 1996
60. Xu H-M, Tepper CG, Jones JB, Fernandez C, Studzinski G: 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Experimental Cell Res 209: 367-374, 1993
61. McElwain MC, Dettelbach MA, Modzelewski RA, Russell DM, Uskokovic MR, Smith DC, Trump DL, Johnson CS: Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Diff 3(1): 31-50, 1995
62. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Shurin Z, Day RS, Trump DL, Johnson CS: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006, 1997
63. Modzelewski RA, Hershberger PA, Johnson CS, Trump DL: Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Amer Assoc Cancer Res 40: 580a, 1999
64. Light BW, Yu W-D, McElwain MC, Russell DM, Trump DL, Johnson CS: Potentiation of cisplatin anti-tumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997
65. Waf1/Cip1 in vitro and in vivo. Cancer Res 59: 2644-2649, 1999
66. Berger NA: Poly (ADP-ribose) in the cellular response to DNA damage. Radiat Res 101: 4-15, 1985
67. Wintersberger U, Wintersberger E: Poly ADP-ribosylation: A cellular emergency reaction? FEBS Lett 188: 189-191, 1985
68. Green DR, Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998
69. Paul A, Wilson S, Belham CM, Robin CJM, Scott PH, Gould GW, Plevin R: Stress-activated protein kinases: Activation, regulation and function. Cell Signal 96: 403-410, 1997
70. Lewis TS, Shaprio PS, Ahn NG: Signal transduction through MAP kinase cascades. Advances in Cancer Res 74: 113-139, 1998
71. McGuire TF, Trump DL, Johnson CS: Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276: 26365-26373, 2001
72. Koli K, Keski-Oja J: 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth & Differentiation 11: 221-229, 2000
73. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81: 730-733, 1999
74. 3 and their combination. Cancer Lett 75: 35-39, 1993
75. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM: Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Opthalmol Vis Sci 36: 83-87, 1995
76. Oikawa T, Horotani K, Nakamura O, Hiragun A, Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48: 157-162, 1989
77. Modzelewski RA, Davies P, Watkins SC, Auerbach R, Ming-Jei C, Johnson CS: Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54: 336-339, 1994
78. Ming-Jei C, Modzelewski RA, Russell DM, Johnson CS: Interleukin 1alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 56(4): 886-891, 1996
79. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL: Anti-proliferative Effects of 1α,25-dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-derived Endothelial Cells (Submitted)
80. Heuser LS, Miller FN: Differential macromolecular leakage from the vasculature of tumors. Cancer 57: 461-464, 1986
81. Gerlowski LE, Jain RK: Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31: 288-305, 1986
82. Hori K, Suzuki M, Tanda S, Saito S: In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81: 279-288, 1990
83. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-109, 1988
84. Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochem Biophys Acta 1032: 89-118, 1990
85. Strom M, Sandgren ME, Brown TA, DeLuca HF: 1,25-Dihydroxyvitamin D3 up-regulates the 1,25-dihydroxyvitamin D3 receptor in vivo. Proc Natl Acad Sci USA 86: 9770-9773, 1989
86. Chen TL, Cone CM, Morey-Holton E, Feldman D: Glucocorticoid regulation of 1,25-(OH)2-vitamin D3 receptors in cultured mouse bone cells. J Biol Chem 257: 13564-13569, 1982
87. Levy J, Zuili I, Yankowitz N, Shany S: Induction of cytosolic receptors for 1,25-dihydroxyvitamin D3 in the immature rat uterus by estradiol. J Endocrinol 100: 265-269, 1984
88. Petkovich PM, Heersche JNM, Tinker DO, Jones G: Retinoic acid stimulates 1,25-dihydroxyvitamin D3 binding in rat osteosarcoma cells. J Biol Chem 259: 8274-8280, 1984
89. Reinhardt TA, Horst RL: Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrin 127: 942-948, 1990
90. Bouillon R, Okamura WH, Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocrine Reviews 16: 200-257, 1995
91. 2-vitamin D3 receptors: Divergent effects on mouse and rat intestine. Endocrin 111: 1400-1402, 1982
92. Hirst M, Feldman D: Glucocorticoids down-regulate the number of 1,25-dihydroxyvitamin D3 receptors in mouse intestine. Biochem Biophys Res Comm 105: 1590-1596, 1982
93. Manolagas SC, Abare J, Deftos LJ: Glucocorticoids increase the 1,25-(OH)2 D3 receptor concentration in rat osteogenic sarcoma cells. Calcif Tissue Int 36: 153-157, 1982
94. Kimberg DV, Baerg RD, Gershon E, Graudusius RT: Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 50: 1309-1321, 1971
95. Haynes RC: Agents affecting calcification: Calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990, pp 1496-1522
96. Yu W-D, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS: Potentiation of 1,25-dihydroxyvitamin D3-mediated anti-tumor activity with dexamethasone. J Natl Cancer Inst 90: 134-141, 1998
97. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS: Combination of 1α,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7: 4164-4173, 2001
98. Norman AW: The mode of action of vitamin D. Biol Rev 243: 4055-4064, 1968
99. 3) Cancer Res 7: 1043-1051, 2001
100. Koeffler HP, Hirji K, Iltri L, The Southern California Leukemia Group: 1,25-Dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69: 1399-1407, 1985
101. French LE, Ramelet AA, Saurat J-H: Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. Lancet 344: 686-687, 1994
102. Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle CS, Soukop M: Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Brit Med J 291: 1153-1155, 1985
103. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A phase I trial of subcutaneous calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345, 1999
104. Beer TM, Munar M, Henner WD: A phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer 91: 2431-2439, 2001
105. Osborne JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL: Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195-198, 1995
106. 3 (calcitriol). J Urol 159: 2035-2040, 1998
107. Davies M: High-dose vitamin D therapy: Indications, benefits and hazards. In: Walter P, Brubacher G, Stahelin H (eds) Elevated Dosages of Vitamins, Vol 81, Hans Huber, Lewistown, NY, 1989
108. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump DL, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. J Clin Oncol 17: 2506-2513, 1999
109. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597, 1989
110. Small EJ, Meyer M, Marshall, ME, Reyno LM, Meyers FJ, Natale RB, Lenchan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18(7): 1440-1450, 2000
111. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, Petrylak DP: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163(3): 834-837, 2000
112. 3) + dexamethasone in androgen independent prostate cancer (AIPC). Proc Amer Soc Clin Oncol 19: 337a, 2000
113. 3) on the pharmacokinetics of paclitaxel or carboplatin: Results of two phase I studies. Proc Amer Soc Oncol 19: 210a, 2000